Literature DB >> 28106896

The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

J K Dart1,2,3.   

Abstract

This review is in two sections. The first section summarises 35 conditions, both common and infrequent, causing cicatrising conjunctivitis. Guidelines for making a diagnosis are given together with the use of diagnostic tests, including direct and indirect immunofluorescence, and their interpretation. The second section evaluates our knowledge of ocular mucous membrane pemphigoid, which is the commonest cause of cicatrizing conjunctivitis in most developed countries. The clinical characteristics, demographics, and clinical signs of the disease are described. This is followed by a review and re-evaluation of the pathogenesis of conjunctival inflammation in mucous membrane pemphigoid (MMP), resulting in a revised hypothesis of the autoimmune mechanisms causing inflammation in ocular MMP. The relationship between inflammation and scarring in MMP conjunctiva is described. Recent research, describing the role of aldehyde dehydrogenase (ALDH) and retinoic acid (RA) in both the initiation and perpetuation of profibrotic activity in MMP conjunctival fibroblasts is summarised and the potential for antifibrotic therapy, using ALDH inhibition, is discussed. The importance of the management of the ocular surface in MMP is briefly summarised. This is followed with the rationale for the use of systemic immunomodulatory therapy, currently the standard of care for patients with active ocular MMP. The evidence for the use of these drugs is summarised and guidelines given for their use. Finally, the areas for research and innovation in the next decade are reviewed including the need for better diagnostics, markers of disease activity, and the potential for biological and topical therapies for both inflammation and scarring.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28106896      PMCID: PMC5306467          DOI: 10.1038/eye.2016.284

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  152 in total

1.  Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept.

Authors:  Christopher Sacher; Andrea Rubbert; Cathrin König; Karin Scharffetter-Kochanek; Thomas Krieg; Nicolas Hunzelmann
Journal:  J Am Acad Dermatol       Date:  2002-01       Impact factor: 11.527

2.  Autoantibodies to basement membrane proteins BP180 and BP230 are commonly detected in normal subjects by immunoblotting.

Authors:  Nemesha Desai; Jill Allen; Iaisha Ali; Vanessa Venning; Fenella Wojnarowska
Journal:  Australas J Dermatol       Date:  2008-08       Impact factor: 2.875

Review 3.  Cicatricial pemphigoid and erythema multiforme.

Authors:  B J Mondino
Journal:  Ophthalmology       Date:  1990-07       Impact factor: 12.079

Review 4.  Diagnosis and classification of autoimmune blistering diseases.

Authors:  Sharon Baum; Nicole Sakka; Ofir Artsi; Henri Trau; Aviv Barzilai
Journal:  Autoimmun Rev       Date:  2014-01-13       Impact factor: 9.754

Review 5.  Pemphigoid diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Lancet       Date:  2012-12-11       Impact factor: 79.321

6.  Treatment of ocular cicatricial pemphigoid with sulfasalazine.

Authors:  S Doan; J F Lerouic; H Robin; C Prost; M Savoldelli; T Hoang-Xuan
Journal:  Ophthalmology       Date:  2001-09       Impact factor: 12.079

7.  The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy.

Authors:  M Victoria De Rojas; John K G Dart; Valerie P J Saw
Journal:  Br J Ophthalmol       Date:  2007-02-21       Impact factor: 4.638

8.  Tumor necrosis factor-alpha in ocular mucous membrane pemphigoid and its effect on conjunctival fibroblasts.

Authors:  Valerie P J Saw; Robin J C Dart; Grazyna Galatowicz; Julie T Daniels; John K G Dart; Virginia L Calder
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-03       Impact factor: 4.799

9.  Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study.

Authors:  V A Venning; P A Frith; A J Bron; P R Millard; F Wojnarowska
Journal:  Br J Dermatol       Date:  1988-01       Impact factor: 9.302

10.  Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy.

Authors:  Nina van Beek; Kristin Rentzsch; Christian Probst; Lars Komorowski; Michael Kasperkiewicz; Kai Fechner; Inga M Bloecker; Detlef Zillikens; Winfried Stöcker; Enno Schmidt
Journal:  Orphanet J Rare Dis       Date:  2012-08-09       Impact factor: 4.123

View more
  14 in total

1.  HLA alleles in British Caucasians with mucous membrane pemphigoid.

Authors:  F Hübner; J Setterfield; A Recke; D Zillikens; E Schmidt; J Dart; S Ibrahim
Journal:  Eye (Lond)       Date:  2018-05-10       Impact factor: 3.775

2.  Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand.

Authors:  Samantha Bobba; Connor Devlin; Nick Di Girolamo; Denis Wakefield; Peter McCluskey; Elsie Chan; Mark Daniell; Stephanie Watson
Journal:  Eye (Lond)       Date:  2018-06-19       Impact factor: 3.775

Review 3.  [Mucous membrane pemphigoid].

Authors:  M M Holtsche; D Zillikens; E Schmidt
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

Review 4.  Molecular mechanisms and treatments for ocular symblephara.

Authors:  Aditi Swarup; Christopher N Ta; Albert Y Wu
Journal:  Surv Ophthalmol       Date:  2021-04-29       Impact factor: 6.048

Review 5.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

6.  Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis.

Authors:  Borja de la Sen-Corcuera; Jesús Montero-Iruzubieta; Ronald M Sánchez-Ávila; Gorka Orive; Eduardo Anitua; Manuel Caro-Magdaleno; Jesús Merayo-Lloves
Journal:  Clin Ophthalmol       Date:  2020-06-17

7.  Urea-De-Epithelialized Human Amniotic Membrane for Ocular Surface Reconstruction.

Authors:  Francisco Bandeira; Gary Hin-Fai Yam; Matthias Fuest; Hon Shing Ong; Yu-Chi Liu; Xin-Yi Seah; Sunny Y Shen; Jodhbir S Mehta
Journal:  Stem Cells Transl Med       Date:  2019-03-13       Impact factor: 6.940

Review 8.  Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment.

Authors:  Panagiotis Georgoudis; Francesco Sabatino; Nora Szentmary; Sotiria Palioura; Eszter Fodor; Samer Hamada; Hendrik P N Scholl; Zisis Gatzioufas
Journal:  Ophthalmol Ther       Date:  2019-01-29

9.  Signaling lipids as diagnostic biomarkers for ocular surface cicatrizing conjunctivitis.

Authors:  Antonio Di Zazzo; Wei Yang; Marco Coassin; Alessandra Micera; Marco Antonini; Fabrizio Piccinni; Maria De Piano; Isabelle Kohler; Amy C Harms; Thomas Hankemeier; Stefano Boinini; Alireza Mashaghi
Journal:  J Mol Med (Berl)       Date:  2020-04-20       Impact factor: 4.599

10.  Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid.

Authors:  W Bernauer; S Schuler; L Borradori
Journal:  J Ophthalmic Inflamm Infect       Date:  2018-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.